Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

taken orally once a day starting cycle 1 day 1 for up to 24 months during the single agent asciminib phase. Asciminib is a potent allosteric inhibitor of BCR::ABL1.

"Low dose tyrosine kinase inhibitor (lowTKI) (dasatinib 50 mg daily or imatinib 300 mg daily or nilotinib 300 mg daily) at investigators discretion, may be added to asciminib in the following situations:~* Patients who have treatment failure at any time based on ELN criteria (Appendix 7)~* Patients who have a warning response after 12 months of single agent asciminib based on ELN criteria (Appendix 7)~* Patients who have not achieved MR4.5 after 24 months, but no later than 36 months, of single agent asciminib."

Once central eligibility has been obtained the patient should discontinue asciminib and if applicable lowTKI within 14 days.